Summary by Futu AI
On June 7, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, announced the entry into an At the Market Offering Agreement with Rodman & Renshaw LLC. Under this agreement, Tharimmune may offer and sell its common stock through Rodman & Renshaw, acting as the sales agent. The sales will be conducted on an 'at the market' basis, meaning they could be made directly on the Nasdaq Stock Market or any other trading market for the company's common stock. Rodman & Renshaw is committed to using commercially reasonable efforts to sell the shares, following the company's instructions, including any imposed limits on price, time, or size of the sales. Tharimmune will pay a commission of 3.0% of the gross proceeds from the sales to Rodman...Show More